GUCY2C

GUCY2C 분자 정보

영어 이름Heat-stable enterotoxin receptor시판 약물 수1
임상 약물 수9표적 별명GUC2C,Intestinal guanylate cyclase,hSTAR,EC:4.6.1.2,EC 4.6.1,GC-C,GUCY2C,Guanylate Cyclase 2C,STA Receptor,Guanylyl Cyclase C,Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor),Heat-Stable Enterotoxin Receptor,STAR,Heat Stable Enterotoxin Receptor,EC 4.6.1.2,DIAR6,MECIL,MUCIL
최고 연구 개발 단계Approved
영어 이름Heat-stable enterotoxin receptor
표적 별명GUC2C,Intestinal guanylate cyclase,hSTAR,EC:4.6.1.2,EC 4.6.1,GC-C,GUCY2C,Guanylate Cyclase 2C,STA Receptor,Guanylyl Cyclase C,Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor),Heat-Stable Enterotoxin Receptor,STAR,Heat Stable Enterotoxin Receptor,EC 4.6.1.2,DIAR6,MECIL,MUCIL
시판 약물 수1
임상 약물 수9
최고 연구 개발 단계Approved

GUCY2C분자 배경

GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.

GUCY2C분자 별명

GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C

라이선싱 협력

프로젝트 이름약물 유형치료 영역적응증단계권리 지역
Anti-GCC humanized antibodyBispecific antibodyOncology/CancerSolid TumorPreclinicalGlobal

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
anti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital)Phase 1 ClinicalHeFei Parasol Biotech Co LtdColorectal Neoplasms
상세
anti-guanylyl cyclase C CAR-T cell therapy (Legend Biotech)LCAR-G08TPhase 1 ClinicalLegend Biotech CorpColorectal Neoplasms; Gastrointestinal Neoplasms
상세
HD-006HD006; HD-006Phase 1 ClinicalHuadao (Shanghai) Biopharma Co LtdSolid tumours
상세
REVO-UWD-01REVO-UWD-01; WD 01Phase 1 ClinicalWondercel Therapeutics Co LtdColorectal Neoplasms
상세
IM96 CAR-T cell TherapyIM96Phase 1 ClinicalImunopharm Technology Co LtdColorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
상세
GCC19CARTGCC19CART; LYL273; LYL-273Phase 1 ClinicalInnovative Cellular Therapeutics Co LtdColorectal Neoplasms; Rectal Neoplasms
상세
Gucy2c cart cell therapy (Innovative Cellular Therapeutics)Phase 1 ClinicalInnovative Cellular Therapeutics Co LtdDigestive System Neoplasms
상세
XKDCT-080XKDCT-080ClinicalThe Affiliated Hospital Of Qingdao UniversityColonic Neoplasms; Solid tumours
상세
CT-080CT-080ClinicalShenzhen Celconta Life Science Co LtdSolid tumours
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
PlecanatideSP-304; GCRAApprovedSynergy Pharmaceuticals IncTrulanceUnited StatesConstipation; Chronic idiopathic constipationSalix Pharmaceuticals2017-01-19Chronic idiopathic constipation; Constipation; Irritable Bowel Syndrome
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호